Name: CEL-SCI CORP (CVM) Stock
Brand: CEL-SCI CORP
Rating: 3 (3 reviews)

CVM Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Stocktwits

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Closing of $10 Million Public Offering

3 months ago - By: Benzinga - Mentions: MBRX CGC PAHC THAR ...

12 Health Care Stocks Moving In Thursday's Intraday Session

3 months ago - By: Benzinga - Mentions: TLX COO GLMD PAHC ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Pricing of $10 Million Public Offering

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Proposed Public Offering

4 months ago - By: CEL-SCI Corporation

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

4 months ago - By: CEL-SCI Corporation

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

5 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

5 months ago - By: Stocktwits - Mentions: VTI IWC

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

5 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

5 months ago - By: CEL-SCI Corporation

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

6 months ago - By: CEL-SCI Corporation

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

7 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Closing of Public Offering

7 months ago - By: CEL-SCI Corporation

CEL-SCI CORP (CVM) Stock News

CVM Latest News, Press Relases and Analysis

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

CEL-SCI Announces Closing of $10 Million Public Offering

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Announces Proposed Public Offering

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering